AR116771A1 - Los neuroesteroides activos y sus métodos de uso - Google Patents
Los neuroesteroides activos y sus métodos de usoInfo
- Publication number
- AR116771A1 AR116771A1 ARP190102988A ARP190102988A AR116771A1 AR 116771 A1 AR116771 A1 AR 116771A1 AR P190102988 A ARP190102988 A AR P190102988A AR P190102988 A ARP190102988 A AR P190102988A AR 116771 A1 AR116771 A1 AR 116771A1
- Authority
- AR
- Argentina
- Prior art keywords
- substituted
- unsubstituted
- heterocyclyl
- heteroaryl
- alkenyl
- Prior art date
Links
- 239000002858 neurotransmitter agent Substances 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 7
- 125000001072 heteroaryl group Chemical group 0.000 abstract 7
- 125000000623 heterocyclic group Chemical group 0.000 abstract 7
- 125000000304 alkynyl group Chemical group 0.000 abstract 6
- 125000003118 aryl group Chemical group 0.000 abstract 6
- 125000004452 carbocyclyl group Chemical group 0.000 abstract 6
- 229910052739 hydrogen Inorganic materials 0.000 abstract 6
- 239000001257 hydrogen Substances 0.000 abstract 6
- 125000003342 alkenyl group Chemical group 0.000 abstract 5
- 150000001875 compounds Chemical class 0.000 abstract 5
- 150000002431 hydrogen Chemical group 0.000 abstract 4
- 150000003839 salts Chemical class 0.000 abstract 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 2
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical group 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 125000006239 protecting group Chemical group 0.000 abstract 2
- 229910052717 sulfur Inorganic materials 0.000 abstract 2
- 239000011593 sulfur Substances 0.000 abstract 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 abstract 1
- 101000743846 Diplobatis ommata Ras-related protein Rab-10 Proteins 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- -1 nitro, hydroxyl Chemical group 0.000 abstract 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000005017 substituted alkenyl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
- C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
- C07J7/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa
- C07J7/002—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa not substituted in position 16
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/008—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21
- C07J7/009—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21 by only one oxygen atom doubly bound
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0003—Androstane derivatives
- C07J1/0007—Androstane derivatives not substituted in position 17
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J13/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
- C07J13/007—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17 with double bond in position 17 (20)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
- C07J7/0065—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by an OH group free esterified or etherified
- C07J7/007—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by an OH group free esterified or etherified not substituted in position 17 alfa
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/008—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21
- C07J7/0085—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21 by an halogen atom
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862748016P | 2018-10-19 | 2018-10-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR116771A1 true AR116771A1 (es) | 2021-06-09 |
Family
ID=68468867
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP190102988A AR116771A1 (es) | 2018-10-19 | 2019-10-21 | Los neuroesteroides activos y sus métodos de uso |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20210363175A1 (https=) |
| EP (2) | EP3867261B1 (https=) |
| JP (2) | JP7534291B2 (https=) |
| CN (1) | CN113227114B (https=) |
| AR (1) | AR116771A1 (https=) |
| AU (2) | AU2019359899B2 (https=) |
| BR (1) | BR112021007401A2 (https=) |
| CA (1) | CA3116892A1 (https=) |
| DK (1) | DK3867261T3 (https=) |
| ES (1) | ES3039267T3 (https=) |
| MX (2) | MX2021004452A (https=) |
| TW (1) | TW202027754A (https=) |
| WO (1) | WO2020082065A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10201606063RA (en) | 2012-01-23 | 2016-09-29 | Sage Therapeutics Inc | Neuroactive steroid formulations and methods of treating cns disorders |
| MX2015002252A (es) | 2012-08-21 | 2015-07-21 | Sage Therapeutics Inc | Metodos para tratar epilepsia o estado de epilepsia. |
| JP6470258B2 (ja) | 2013-04-17 | 2019-02-13 | セージ セラピューティクス， インコーポレイテッド | １９−ノルｃ３，３−ジ置換ｃ２１−ｎ−ピラゾリルステロイドおよびその使用方法 |
| WO2015195962A1 (en) | 2014-06-18 | 2015-12-23 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| JOP20200195A1 (ar) | 2014-09-08 | 2017-06-16 | Sage Therapeutics Inc | سترويدات وتركيبات نشطة عصبياً، واستخداماتها |
| WO2016082789A1 (en) | 2014-11-27 | 2016-06-02 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| TWI904593B (zh) | 2016-08-23 | 2025-11-11 | 美商賽吉醫療公司 | 結晶19-去甲c3,3-二取代之c21-n-吡唑類固醇 |
| EP3720867A1 (en) | 2017-12-08 | 2020-10-14 | Sage Therapeutics, Inc. | Deuterated 21 -[4-cyano-pyrazol-1 -yl]-19-nor-pregan-3. alpha-ol-20-one derivatives for treating cns disorders |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3953429A (en) * | 1970-12-17 | 1976-04-27 | Glaxo Laboratories Limited | Anaesthetic steroids of the androstance and pregnane series |
| DE2526373C2 (de) * | 1975-06-11 | 1983-11-10 | Schering AG, 1000 Berlin und 4709 Bergkamen | Verfahren zur Herstellung von Δ↑9↑↑(↑↑1↑↑1↑↑)↑-5α-20-Ketosteroiden |
| JP2545522B2 (ja) * | 1985-10-23 | 1996-10-23 | アルコン・ラボラトーリーズ，インコーポレイテッド | テトラヒドロ脈管形成抑制ステロイド |
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| AU3967297A (en) * | 1996-08-01 | 1998-02-25 | Cocensys, Inc. | Use of gaba and nmda receptor ligands for the treatment of migraine headache |
| US10577390B2 (en) * | 2014-10-16 | 2020-03-03 | Sage Therapeutics, Inc. | Compositions and methods for treating CNS disorders |
| MA45599A (fr) * | 2016-07-11 | 2019-05-15 | Sage Therapeutics Inc | Stéroïdes neuroactifs substitués en c17, c20 et c21 et leurs procédés d'utilisation |
-
2019
- 2019-10-21 CA CA3116892A patent/CA3116892A1/en active Pending
- 2019-10-21 EP EP19798489.1A patent/EP3867261B1/en active Active
- 2019-10-21 ES ES19798489T patent/ES3039267T3/es active Active
- 2019-10-21 MX MX2021004452A patent/MX2021004452A/es unknown
- 2019-10-21 JP JP2021521085A patent/JP7534291B2/ja active Active
- 2019-10-21 TW TW108137951A patent/TW202027754A/zh unknown
- 2019-10-21 DK DK19798489.1T patent/DK3867261T3/da active
- 2019-10-21 US US17/286,524 patent/US20210363175A1/en not_active Abandoned
- 2019-10-21 WO PCT/US2019/057195 patent/WO2020082065A1/en not_active Ceased
- 2019-10-21 CN CN201980083218.9A patent/CN113227114B/zh active Active
- 2019-10-21 EP EP25172672.5A patent/EP4606812A3/en active Pending
- 2019-10-21 AR ARP190102988A patent/AR116771A1/es unknown
- 2019-10-21 AU AU2019359899A patent/AU2019359899B2/en active Active
- 2019-10-21 BR BR112021007401-5A patent/BR112021007401A2/pt unknown
-
2021
- 2021-04-16 MX MX2024014845A patent/MX2024014845A/es unknown
-
2024
- 2024-05-07 JP JP2024075254A patent/JP2024096347A/ja active Pending
- 2024-09-30 AU AU2024220209A patent/AU2024220209A1/en active Pending
- 2024-11-07 US US18/940,062 patent/US20250136638A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| BR112021007401A2 (pt) | 2021-08-03 |
| AU2024220209A1 (en) | 2024-10-17 |
| US20210363175A1 (en) | 2021-11-25 |
| EP3867261A1 (en) | 2021-08-25 |
| EP3867261B1 (en) | 2025-04-30 |
| TW202027754A (zh) | 2020-08-01 |
| EP4606812A2 (en) | 2025-08-27 |
| JP7534291B2 (ja) | 2024-08-14 |
| JP2022505146A (ja) | 2022-01-14 |
| US20250136638A1 (en) | 2025-05-01 |
| AU2019359899B2 (en) | 2024-07-04 |
| ES3039267T3 (en) | 2025-10-20 |
| CA3116892A1 (en) | 2020-04-23 |
| WO2020082065A1 (en) | 2020-04-23 |
| CN113227114A (zh) | 2021-08-06 |
| MX2021004452A (es) | 2021-08-11 |
| AU2019359899A1 (en) | 2021-05-20 |
| CN113227114B (zh) | 2026-01-27 |
| EP4606812A3 (en) | 2025-10-15 |
| MX2024014845A (es) | 2025-01-09 |
| JP2024096347A (ja) | 2024-07-12 |
| DK3867261T3 (da) | 2025-08-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR116771A1 (es) | Los neuroesteroides activos y sus métodos de uso | |
| AR114044A1 (es) | Composiciones y métodos para el tratamiento de trastornos en el sistema nervioso central | |
| PE20252777A1 (es) | Inhibidores macrociclicos de ras | |
| AR044909A1 (es) | Derivados de tiazolilpiperidina, procesos para su preparacion, composiciones farmaceuticas que los comprenden y aplicaciones de dichos derivados en el tratamiento de hipertrigliceridemia , hipercolesterolemia y dislipidemia | |
| AR054035A1 (es) | Derivados benzodioxano y benzodioxolano y uso de los mismos | |
| PE20242099A1 (es) | Compuestos de piridotriazina sustituidos y usos de estos | |
| ES2530943T3 (es) | Derivados de la cromenona con actividad antitumoral | |
| AR075587A1 (es) | Derivados de bifenilo para el tratamiento de hepatitis c | |
| AR096979A1 (es) | Derivados de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
| AR063602A1 (es) | Derivados de espiroindolinona, formulaciones farmaceuticas que los contienen y su uso en la obtencion de un medicamento para el tratamiento de trastornos oncologicos. | |
| AR045901A1 (es) | Glucocorticoesteroides especificos con actividades antiinflamatoria y antialergica,composiciones farmaceuticas que los contienen,y procedimientos para su preparacion, | |
| AR123648A1 (es) | Compuestos de carbamoilpiridona tricíclicos puenteados y sus usos | |
| AR114679A1 (es) | Compuestos heterocíclicos fungicidas | |
| CR20220638A (es) | Derivados de amidopirimidona | |
| DOP2010000022A (es) | Derivados de pirimidina 934 | |
| CO2022003123A2 (es) | Compuestos farmacéuticos | |
| MX2020009530A (es) | Inhibidores de la o-glicoproteína-2-acetamido-2-desoxi-3-dglicopir anosidasa. | |
| UY29312A1 (es) | Piperazin-1-carboxamidas n,4,sustituidas y sus derivados, composiciones que los contienen, procedimientos de preparación y aplicaciones | |
| AR065249A1 (es) | Derivados nitrogenados condensados de analogos de nucleosidos, composiciones farmaceuticas que los contienen y usos para tratar y/o prevenir infecciones virales. | |
| AR115007A1 (es) | Derivados de triazolona o sales de los mismos y composiciones farmacéuticas que comprenden los mismos | |
| PY2228191A (es) | Nuevos derivados de heteroaril aminopropanol | |
| CL2020001817A1 (es) | Moduladores del receptor c5a | |
| PE20230182A1 (es) | Uso y composicion farmaceutica de derivados de fenilisoxazolil metilen-naftaleno-eter | |
| AR061185A1 (es) | Compuestos heterociclicos como inhibidores de hsp90. composiciones farmaceuticas. | |
| CL2023000387A1 (es) | Derivados de dioxoloisoquinolinona novedosos y uso de los mismos |